Sipatrigine could have therapeutic potential for major depression and bipolar depression through antagonism of the two-pore-domain K+ channel TREK-1

Medical Hypotheses

Volumn 70, Issue 3, 2008, Pages 548-550

  Tsai, Shih Jen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; FLUOXETINE; GLUTAMIC ACID; LAMOTRIGINE; NORFLUOXETINE; POTASSIUM CHANNEL; PROTEIN TREK 1; SIPATRIGINE; UNCLASSIFIED DRUG;

ARTICLE; BIPOLAR DEPRESSION; DRUG MECHANISM; DRUG PROTEIN BINDING; FOOD AND DRUG ADMINISTRATION; MAJOR DEPRESSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BIPOLAR DISORDER; BRAIN; DEPRESSIVE DISORDER; HUMANS; MICE; MODELS, ANIMAL; NEUROPROTECTIVE AGENTS; PIPERAZINES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; PYRIMIDINES;

ANIMALIA; MUS;

EID: 38749109246     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.06.030     Document Type: Article

References (17)

1. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psych 53 (2003) 649-659
2. Sackeim H.A. The definition and meaning of treatment-resistant depression. J Clin Psych 62 Suppl. 16 (2001) 10-17
3. Medhurst A.D., Rennie G., Chapman C.G., Meadows H., Duckworth M.D., Kelsell R.E., et al. Distribution analysis of human two pore domain potassium channels in tissues of the central nervous system and periphery. Brain Res Mol Brain Res 86 (2001) 101-114
4. Duman R.S., Malberg J., and Thome J. Eural plasticity to stress and antidepressant treatment. Biol Psych 46 (1999) 1181-1191
5. Heurteaux C., Guy N., Laigle C., Blondeau N., Duprat F., Mazzuca M., et al. TREK-1, a K+ channel involved in neuroprotection and general anesthesia. EMBO J 23 (2004) 2684-2695
6. Alloui A., Zimmermann K., Mamet J., Duprat F., Noel J., Chemin J., et al. TREK-1, a K+ channel involved in polymodal pain perception. EMBO J 25 (2006) 2368-2376
7. Honore E. The neuronal background K2P channels: focus on TREK1. Nat Rev Neurosci 8 (2007) 251-261
8. Heurteaux C., Lucas G., Guy N., El Yacoubi M., Thummler S., Peng X.D., et al. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci 9 (2006) 1134-1141
9. Gordon J.A., and Hen R. TREKing toward new antidepressants. Nat Neurosci 9 (2006) 1081-1083
10. Kennard L.E., Chumbley J.R., Ranatunga K.M., Armstrong S.J., Veale E.L., and Mathie A. Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br J Pharmacol 144 (2005) 821-829
11. Hainsworth H.A., Stefani A., Calabresi P., Smith T.W., and Leach M.J. Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor. CNS Drug Rev 6 (2000) 111-134
12. Leach M.J., Swan J.H., Eisenthal D., Dopson M., and Nobbs M. BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke 24 (1993) 1063-1067
13. Meadows H.J., Chapman C.G., Duckworth D.M., Kelsell R.E., Murdock P.R., Nasir S., et al. The neuroprotective agent sipatrigine (BW619C89) potently inhibits the human tandem pore-domain K(+) channels TREK-1 and TRAAK. Brain Res 892 (2001) 94-101
14. Oral E.T., and Vahip S. Bipolar depression: an overview. IDrugs 7 (2004) 846-850
15. Gutierrez R.L., McKercher R.M., Galea J., and Jamison K.L. Lamotrigine augmentation strategy for patients with treatment-resistant depression. CNS Spectr 10 (2005) 800-805
16. Krystal J.H., Sanacora G., Blumberg H., Anand A., Charney D.S., Marek G., et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psych 7 Suppl. 1 (2002) S71-S80
17. Mineur Y.S., Picciotto M.R., and Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol Psych 61 (2007) 250-252